Do We Need the Final Results of the ERSPC Trial?

European Urology

Volumn 51, Issue 2, 2007, Pages 291-292

  Albers, Peter ^a  

^a KLINIKUM KASSEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER RESEARCH; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; EDITORIAL; HUMAN; MEDICAL LITERATURE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PUBLICATION; RANDOMIZATION; SCREENING TEST; SURVIVAL RATE;

EUROPE; HUMANS; MALE; MASS SCREENING; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE;

EID: 33845597432     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.07.044     Document Type: Editorial

References (8)

1. de Vries S.H., Postma R., Raaijmakers R., et al. Overall and disease-specific survival of patients with screen-detected prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Eur Urol. 51 (2007) 366-374
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
3. Roemeling S., Roobol M.J., Gosselaar C., and Schroder F.H. Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Prostate 66 (2006) 1076-1081
4. Postma R., van Leenders A.G.J.L.H., Roobol M.J., Schröder F.H., and van der Kwast T.H. Tumour features in the control and screening arm of a randomized trial of prostate cancer. Eur Urol 50 (2006) 70-75
5. Klotz L. Active surveillance for prostate cancer: for whom?. J Clin Oncol 23 (2005) 8165-8169 (review)
6. Roemeling S., Roobol M.J., Postma R., et al. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. Eur Urol 50 (2006) 475-482
7. Loeb S., Roehl K.A., Antenor J.A., Catalona W.J., Suarez B.K., and Nadler R.B. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 67 (2006) 316-320
8. Bill-Axelson A., Holmberg L., Ruutu M., et al., Scandinavian Prostate Cancer Group Study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352 (2005) 1977-1984